INS and diabetes mellitus: Use of sulfonylureas and insulin carries a greater risk of hypoglycemia than diabetes medications acting via alternative mechanisms, including GLP-1 RAs such as liraglutide and DPP4 inhibitors such as sitagliptin [11,12].